Last night at JPM: The Future of Aging. Co-hosted with Cooley + @Stifel, featuring our CEO @felixjwong alongside @bettslacroix (@RetroBio_), @jacobkimmel (@newlimit), @TimOpler (Stifel), Hanadie Yousef (Juvena Therapeutics), and Mike Nelson (Cooley).

From landmark publications (Nature Protocols, 2× Cell) to doubling our team and strengthening our platform, 2025 was a big year. We wrapped it up with our inaugural R&D Day, bringing together our team and collaborators to share rapid progress across our small-molecule pipeline for age-related diseases and our platform at the intersection of biology, chemistry, and AI. Heading into 2026 with momentum and ready to break new ground.

Excited to host The Future of Aging on Monday at JPM 2026! Expect insights, dynamic discussion, and networking over cocktails with senior leaders from pharma, biotech, venture, and healthcare innovation.

Pharma R&D is hitting an inflection point. At #GapSummit2025, we joined @AstraZeneca, @NovoNordisk, @Microsoft, and @BCG to dig into where AI is already changing the game—from data-rich discovery to physics-driven modeling. Our belief at Integrated: the real breakthroughs will come from combining differentiated data, domain-tuned AI, and rigorous experimental validation. That fusion is already revealing new targets and compounds for age-related diseases. A fantastic panel and an exceptional summit at Cambridge. @Cambridge_Uni #DrugDiscovery #AI #Pharma #Aging #Innovation #Therapeutics #DeepLearning

We’re incredibly lucky to have Sir David MacMillan on our Scientific Advisory Board. In this short clip that his team at Princeton recorded for our R&D Day, Dave shares why he’s excited about Integrated Biosciences and why the science we’re building together matters. Dave is the James S. McDonnell Distinguished University Professor of Chemistry at Princeton and a 2021 Nobel Prize laureate for pioneering asymmetric organocatalysis. @dmac68 @shv @MIT @Harvard @Princeton @PrincetonChem #PrincetonChemistry #NobelPrize #Biotech #AgingScience #DeepTech #DrugDiscovery

Super engaging panel discussion about opportunities in AI for aging drug discovery from the co-founder of @xai, @Yuhu_ai_ , and both our CEO @felixjwong and Head of AI @alex_peys at Integrated

Super excited to kick off our inaugural R&D at Integrated! Today will be an exciting day full of company updates and exciting talks from leaders in the field of synthetic biology, chemistry and AI!

Last month’s AI in Drug Discovery event showed just how quickly the field is advancing. At Integrated, we’re building age-relevant, high-fidelity datasets, from omics to whole-organism biology, to power our graph neural networks, multimodal models, and generative AI. Big thank you to @SiliconVlyBank bank for organizing this event, and to the fellow panelists from @EliLillyandCo , @tamarindbio , @CivilizationVC, @AP_LifeSciences , and Trinet for joining our CEO @felixjwong in a dynamic discussion bridging science, AI, transactions, regulations, and IP.

The intelligence layer powering discovery. Our AI engine is trained on internally generated, high-fidelity, multimodal datasets focused on aging biology—spanning cellular, molecular, and phenotypic levels—to uncover previously inaccessible targets and compounds.